| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Arvind Kush is Director at IKT. Arvind Kush's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $215K at current prices.
Net of sales, the IKT filings show accumulation of 145,000 shares.
Arvind Kush has 4 Form 4 filings on record from October 2024 to June 2026, all as Director at Inhibikase Therapeutics (IKT), 2024–2026.
The 6 reported transactions were 5 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $199K and no sales.
The only open-market purchase was 145,000 shares of IKT at an average $1.37 on October 21, 2024, about $199K. Twelve months later IKT was down 29%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 21, 2024 | IKT Inhibikase Therapeutics, Inc. | Director | Buy | 145,000 | $1.37 | $198,650.00 | New | +26.6% | -28.8% |